Rigel Pharma downgraded by Piper Sandler with a new price target
$RIGL
Biotechnology: Pharmaceutical Preparations
Health Care
Piper Sandler downgraded Rigel Pharma from Overweight to Neutral and set a new price target of $1.00 from $7.00 previously
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
4/3/2023 | $2.00 | Neutral | Piper Sandler |
6/9/2022 | Buy → Neutral | Citigroup | |
6/8/2022 | $7.00 → $1.00 | Overweight → Neutral | Piper Sandler |
6/8/2022 | $6.00 → $1.00 | Overweight → Neutral | Cantor Fitzgerald |
3/23/2022 | $4.00 | Neutral | B. Riley Securities |